Industry: Pharmaceuticals, Biotechnology
Origen Therapeutics is a biotechnology company developing product opportunities arising from the emerging field of avian transgenic animal technology. The company’s mission is to become the leading developer of a novel class human immunotherapeutics known as fully human sequence polyclonal antibodies. These antibodies are expected to have significant advantages over monoclonal antibodies that currently are in great favor amongst developers of human therapeutics. Origen plans to create corporate alliances with biotechnology and large pharmaceutical companies for the commercialization of these products. Origen’s business is characterized by: A broad-based technology platform offering a wide array of immuntherapeutic ( www.origentherapeutics.com )
Origen Therapeutics Inc
1450 Rollins Road
Burlingame, California 94010
USA
Tel: (650) 558-6700
Fax: (650) 558-7799